Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Business Wire•20/10/2026•01:00 ET
0
Key Highlights
- ➤Third-quarter 2026 business update scheduled for November 5, 2026
- ➤Conference call set for 2 p.m. CET / 8 a.m. ET
- ➤Innate Pharma advances IPH4502 Nectin-4 ADC in clinical development
- ➤Partnered assets include lacutamab with Sobi and monalizumab with AstraZeneca
Expert Statements
Jonathan Dickinson, Chief Executive Officer of Innate Pharma
“Jonathan Dickinson”
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update for the third quarter of 2026.
Get started
Create a free account to read the full story.